HCWB Stock Summary and Trading Ideas (HCW Biologics | NASDAQ:HCWB)

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

HCW Biologics trades on the NASDAQ stock market under the symbol HCWB.

As of September 8, 2026, HCWB stock price declined to $2.51 with 834,101 million shares trading.

HCWB has a beta of 3.16, meaning it tends to be more sensitive to market movements. HCWB has a correlation of 0.03 to the broad based SPY ETF.

HCWB has a market cap of $4.61 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, HCWB traded as high as $604.80 and as low as $1.50.

The top ETF exchange traded funds that HCWB belongs to (by Net Assets): VXF.

HCWB has underperformed the market in the last year with a return of -91.0%, while the SPY ETF gained +19.2%. In the last 3 month period, HCWB fell short of the market, returning -74.3%, while SPY returned +1.4%. However, in the most recent 2 weeks HCWB has outperformed the stock market by returning +15.1%, while SPY returned 0.0%.

HCWB support price is $2.67 and resistance is $3.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCWB shares will trade within this expected range on the day.